Below are all the posts — topics as well as replies — that mention the hashtag #biotech.
Mention #biotech in your post to continue the discussion!
Charles River Laboratories recorded a net loss in the first quarter. The company also disclosed plans to lay off 71 employees. A one-time $118 million charge from asset sales led to the net loss. Without this charge, adjusted earnings per share beat expectations. New CEO Birgit Girshick introduced a strategic framework for future operations.
Wilmington, Massachusetts
https://www.masslive.com/news/2026/05/charles-river-laboratories-posts-loss-amid-dozens-of-layoffs-says-turnaround-on-track.html
Biotech layoffs are slowing in 2026 compared to the previous year. BioNTech announced a major restructuring, eliminating 1,860 jobs. Vistagen reduced its workforce by 20% after a dr-g trial failure. Replimune cut 224 positions following an FDA dr-g rejection. Takeda and Merck also implemented significant job reductions due to various pressures.
https://www.pharmavoice.com/news/biotech-layoffs-pharma-dr-g-jobs/819649/
Biontech plans significant production cuts. This German company will reduce its workforce. Approximately 1,800 staff members will depart. Decreased demand for COVID-19 vaccines drives this decision. Biontech developed its vaccine with Pfizer.
https://medwatch.com/article19266743.ece
Passage Bio will reduce its workforce by 75%. This follows tough feedback from the FDA regarding its lead gene therapy. The FDA did not support a single-arm trial for the PBFT02 candidate. Passage Bio has also launched a strategic review for the company. This review includes exploring options like a merger, sale, or partnership.
Philadelphia, Pennsylvania
https://www.fiercebiotech.com/biotech/passage-launches-strategic-review-and-75-layoffs-after-gene-therapy-path-blocked-fda
Replimune Group Inc. laid off 224 Massachusetts employees last week. These cuts followed the FDA's second rejection of its lead cancer dr-g, RP1. The layoffs occurred across two facilities in Woburn and Framingham. The first wave eliminated 63 positions, followed by 161 additional cuts. Company filings suggest more employee reductions may be finalized soon.
Woburn, Massachusetts
https://www.masslive.com/news/2026/04/200-mass-biotech-employees-were-laid-off-last-week-that-may-only-be-the-beginning.html
Allied Group LLC will lay off 154 employees. This was reported to the Rhode Island Department of Labor and Training. The company offers fulfillment services. It supports life science and biotech companies. Employee separations are scheduled to begin on May 25.
Rhode Island
https://turnto10.com/news/local/allied-group-llc-to-layoff-over-150-employees-in-rhode-island
Less than a year after cutting 25% of its workforce, Bicycle Therapeutics is once again making layoffs. This time, the biotech is set to reduce its workforce by 30%. Because Bicycle had 288 employees at the start of 2026, this means about 86 workers are set to lose their jobs in this round of layoffs.
https://www.nbcboston.com/boston-business-journal/massachusetts-biotech-cuts-30-of-workforce-winds-down-lead-dr-g/3917165/
https://www.fiercebiotech.com/biotech/evotec-reveals-sweeping-800-person-layoffs-more-site-closures-restructuring-rolls
Alltrna, a Flagship Pioneering-backed biotech, recently laid off 19 employees. This marks the company's third workforce reduction. The decision aims to prepare Alltrna for clinical trials of its tRNA dr-g candidate. After the layoffs, 36 staffers remain at the Cambridge, Mass.-based company. Alltrna focuses on developing tRNA medicines for genetic liver diseases.
https://www.fiercebiotech.com/biotech/alltrna-undergoes-third-layoff-round-entering-clinic-cutting-35-jobs
No number out, but cuts have been reported.
https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026
Charles River Closes Maryland Cell Therapy Site, Cuts 20 Jobs
Charles River Laboratories is closing its cell therapy CDMO site in Hanover, Maryland. This closure will result in 20 employee layoffs. The decision is part of a broader company restructuring. Other Charles River facilities will take over client work by mid-2026. The company aims to optimize its business and save $70 million annually by 2026.
https://www.fiercebiotech.com/cro/charles-river-close-cell-therapy-cdmo-site-lay-20-staffers
More biotech companies continue to reduce their workforce, with layoffs stretching into mid-2026, underscoring the sustained pressure facing the sector as funding remains tight and strategic priorities shift.
https://www.biospace.com/biospace-layoff-tracker
A company spokesperson confirmed that the job cuts will impact staff at its San Francisco headquarters as well as remote employees working from Seattle.
https://www.biospace.com/biospace-layoff-tracker
Tessera’s layoffs come amid broader biotech industry adjustments, with the company narrowing its research scope to core gene-editing efforts tied to its partnership with Regeneron and moving other projects
https://www.boston.com/news/business/2026/01/12/somerville-biotech-company-laying-off-35-of-workforce/
Tessera Therapeutics is planning to lay off 90 employees, the Flagship-founded biotech has warned.
In a state layoff notice posted Wednesday, Tessera explained that the workforce reduction will affect employees based in a number of U.S. states starting March 8.
https://www.fiercebiotech.com/biotech/flagship-founded-tessera-plans-lay-90-employees-march
https://globalbiodefense.com/2025/07/03/trump-vance-research-cuts-biotech-warning-2025/
After winning an approval decades in the making last year—and shuffling its executive roster throughout 2025—Geron Corporation is scaling back its head count.
https://www.fiercepharma.com/pharma/geron-lay-13-workforce-quest-slash-operating-costs-maximize-rytelo-launch
I heard from my colleagues that there was another round this morning. Anybody else heard about this?
TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers.
https://www.fiercebiotech.com/biotech/tscan-lays-30-workforce-halts-phase-1-solid-tumor-t-cell-receptor-trial
Title speaks for itself. There have been some significant departures within Quality leadership recently. Anyone have any insights?
Roche’s Genentech unit is laying off staff at its Bay Area headquarters for at least the third time this year, saying goodbye to 118 employees in a workforce reduction that spans multiple departments.
https://www.fiercebiotech.com/biotech/genentech-says-goodbye-118-employees-third-hq-layoff-round-year
What do you all think? Does that mean imminent layoffs in US/UK?
Novo Nordisk, the Danish dr-g manufacturer behind the weight-loss and diabetes dr-g Ozempic and other medications, said it's paying up to $5.2 billion to buy Akero Therapeutics, a biotech company with a dr-g in a late-stage trial to treat a fatal liver disease.
https://www.morningstar.com/news/marketwatch/20251009145/novo-nordisk-is-paying-up-to-52-billion-for-a-san-francisco-biotech-working-on-liver-disease
The Massachusetts biotech sector is facing its steepest round of job cuts in more than a year, with 27 companies eliminating a combined 1,800 jobs during the third quarter of 2025, according to the Boston Business Journal. This marks the highest quarterly loss of biotech positions since the second quarter of 2024, underscoring ongoing financial and market pressures within the industry.
The layoffs span a wide range of organizations, from major pharmaceutical employers to smaller research-driven startups. Companies that reduced staff include IO Biotech, KALA Bio, Sutro Biopharma, Biogen, Heidelberg Pharma, Rome Therapeutics, Seres Therapeutics, Arvinas, Novo Nordisk, Bristol Myers Squibb, Arsenal Biosciences, X4 Pharmaceuticals, and Innate Pharma. Collectively, the cuts affected roles across dr-g development, research, operations, and administrative functions.
Industry analysts point to a combination of factors driving the reductions: slowing deal activity, tighter funding conditions for emerging companies, and strategic pipeline shifts among larger pharmaceutical players. Some firms cited the need to focus resources on late-stage programs or more commercially promising therapies, while others faced direct setbacks such as failed trials or lost partnerships.
Despite the downturn, Massachusetts remains one of the nation’s most active biotech hubs, with billions of dollars in venture investment and ongoing expansion projects. However, the rising tally of layoffs has raised concerns about the sustainability of growth in the sector. Industry observers note that while some displaced workers may find opportunities in better-funded or expanding biotech firms, the wave of cuts highlights an increasingly challenging environment for both startups and established players.
Exelixis
https://www.sfgate.com/tech/article/bay-area-biotech-company-worth-10-billion-layoff-21020576.php
Massachusetts Biotech Sector Faces Slowdown in Venture Funding and Increased Layoffs
A new report from the Massachusetts Biotechnology Council (MassBio) has outlined concerning trends within the state's biotech sector.
https://www.geneonline.com/massachusetts-biotech-sector-faces-slowdown-in-venture-funding-and-increased-layoffs/
GeneOnline
Aug/26/2025 09:24 PM
Location: Massachusetts
Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell Labs model to biotech.
https://www.fiercebiotech.com/biotech/arena-bioworks-19-months-after-splashy-launch-lays-30-its-staff
Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell Labs model to biotech.
Changes at Arena BioWorks follow events that have shaken confidence in gene therapies.
https://www.fiercebiotech.com/biotech/arena-bioworks-19-months-after-splashy-launch-lays-30-its-staff
gilead sciences (tmunity therapeutics) – philadelphia, pennsylvania – biotech cell therapy division – shut down center city office – last 14 positions eliminated by end of june 2025 – part of office consolidation under kite pharma – former east norriton manufacturing facility now operated by resilience
https://www.nbcboston.com/boston-business-journal/mass-cancer-biotech-cuts-25-of-its-workforce/3787827/